Abstract
A GLP-1 Receptor Agonist Looks Promising in Phase 2 Study for Parkinson's Disease
Full Text
Sign-in/Register to access full text options
Published version (Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have